Table 2.
Drug | PL group n (%) | PR group n (%) |
---|---|---|
Camrelizumab | 11 (34.38) | 15 (51.72) |
Pembrolizumab | 1 (3.13) | 0 |
Nivolumab | 1 (3.13) | 0 |
Sintilimab | 12 (37.5) | 7 (24.14) |
Toripalimab | 7 (21.88) | 5 (17.24) |
Tislelizumab | 0 | 2 (6.90) |
Drug | PL group n (%) | PR group n (%) |
---|---|---|
Camrelizumab | 11 (34.38) | 15 (51.72) |
Pembrolizumab | 1 (3.13) | 0 |
Nivolumab | 1 (3.13) | 0 |
Sintilimab | 12 (37.5) | 7 (24.14) |
Toripalimab | 7 (21.88) | 5 (17.24) |
Tislelizumab | 0 | 2 (6.90) |